Page 314 - IJB-8-4

Vessel-on-a-Chip for Antiangiogenic Drug Screening
Pharm Sci, 15:529–57. https://doi.org/10.1016/j.biomaterials.2014.05.083
28. He Y, Xie M, Gao Q, et al., 2019, Why Choose 3D 40. Gao G, Park JY, Kim BS, et al., 2018, Coaxial Cell Printing
Bioprinting? Part I: A Brief Introduction of 3D Bioprinting of Freestanding, Perfusable, and Functional in vitro Vascular
for the Beginners. Biodes Manuf, 3:1–4. Models for Recapitulation of Native Vascular Endothelium
29. Yang Q, Lv X, Gao B, et al, 2021, Mechanics of Hydrogel-based Pathophysiology. Adv Healthc Mater, 7:e1801102.
Bioprinting: From 3D to 4D. Adv Appl Mech, 54:285–318. https://doi.org/10.1002/adhm.201801102
30. Zhang Y, Duchamp M, Oklu R, et al., 2016, Bioprinting the 41. Cui H, Zhu W, Huang Y, et al., 2019, In vitro and in vivo
Cancer Microenvironment. ACS Biomater Sci Eng, 2:1710–21. Evaluation of 3D Bioprinted Small-diameter Vasculature with
31. Kinstlinger IS, Miller JS, 2016, 3D-printed Fluidic Networks Smooth Muscle and Endothelium Biofabrication, 12:015004.
as Vasculature for Engineered Tissue. Lab Chip, 16:2025–43. https://doi.org/10.1088/1758-5090/ab402c
32. Gao Q, He Y, Fu JZ, et al., 2015, Coaxial Nozzle-assisted 42. Pennings I, Van Haaften EE, Jungst T, et al., 2019, Layer-
3D Bioprinting with Built-in Microchannels for Nutrients specific Cell Differentiation in Bi-layered Vascular Grafts
Delivery. Biomaterials, 61:203–15. under Flow Perfusion. Biofabrication, 12:015009.
https://doi.org/10.1016/j.biomaterials.2015.05.031 https://doi.org/10.1088/1758-5090/ab47f0
33. Gao Q, Liu Z, Lin Z, et al., 2017, 3D Bioprinting of Vessel- 43. Available from: https://www.cancer.gov/about-cancer/
like Structures with Multilevel Fluidic Channels. ACS treatment/types/immunotherapy/angiogenesis-inhibitors-
Biomater Sci Eng, 3:399–408. fact-sheet [Last accessed on 2022 Aug 22].
https://doi.org/10.1021/acsbiomaterials.6b00643 44. McCormack PL, Keam SJ, 2008, Bevacizumab. Drugs,
34. Ouyang L, Highley CB, Sun W, et al., 2017, A Generalizable 68:487–506.
Strategy for the 3D Bioprinting of Hydrogels from Nonviscous 45. Blick SK, Keating GM, Wagstaff AJ, 2007, Ranibizumab.
Photo-crosslinkable Inks. Adv Mater, 29: 1604983. Drugs, 67:1199–206.
https://doi.org/10.1002/adma.201604983 https://doi.org/10.2165/00003495-200767080-00007
35. Jia W, Gungor-Ozkerim PS, Zhang YS, et al., 2016, Direct 46. Javle M, Smyth EC, Chau I, 2014, Ramucirumab: Successfully
3D Bioprinting of Perfusable Vascular Constructs Using a Targeting Angiogenesis in Gastric Cancer. Clin Cancer Res,
Blend Bioink. Biomaterials, 106:58–68. 20:5875–81.
https://doi.org/10.1016/j.biomaterials.2016.07.038 https://doi.org/10.1158/1078-0432.CCR-14-1071
36. Gao G, Lee JH, Jang J, et al., 2017, Tissue Engineered Bio- 47. Holash J, Davis S, Papadopoulos N, et al., 2002, VEGF-Trap:
blood-vessels Constructed Using a Tissue-specific Bioink A VEGF Blocker with Potent Antitumor Effects. Proc Nat
and 3D Coaxial Cell Printing Technique: A Novel Therapy Acad Sci U S A, 99:11393–8.
for Ischemic Disease. Adv Funct Mater, 27:1700798. https://doi.org/10.1073/pnas.172398299
https://doi.org/10.1002/adfm.201700798 48. Ciombor KK, Berlin J, Chan E, 2013, Aflibercept. Clin
37. Shao L, Gao Q, Zhao H, et al., 2018, Fiber-based Mini Tissue Cancer Res, 19:1920–5.
with Morphology-controllable GelMA Microfibers. Small, https://doi.org/10.1158/1078-0432.CCR-12-2911
14:e1802187. 49. Wilhelm SM, Dumas J, Adnane L, et al., 2011, Regorafenib
https://doi.org/10.1002/smll.201802187 (BAY 73-4506): A New Oral Multikinase Inhibitor of
38. Shao L, Gao Q, Xie C, et al., 2020, Directly Coaxial 3D Angiogenic, Stromal and Oncogenic Receptor Tyrosine
Bioprinting of Large-scale Vascularized Tissue Constructs. Kinases with Potent Preclinical Antitumor Activity. Int J
Biofabrication, 12:035014. Cancer, 129:245–55.
https://doi.org/10.1088/1758-5090/ab7e76 https://doi.org/10.1002/ijc.25864
39. Lee VK, Kim DY, Ngo H, et al., 2014, Creating Perfused 50. Strumberg D, Schultheis B, 2012, Regorafenib for Cancer.
Functional Vascular Channels Using 3D Bio-printing Expert Opin Investig Drugs, 21:879–89.
Technology. Biomaterials, 35:8092–102. https://doi.org/10.1517/13543784.2012.684752

Publisher’s note
Whioce Publishing remains neutral with regard to
jurisdictional claims in published maps and institutional
affiliations.

306 International Journal of Bioprinting (2022)–Volume 8, Issue 4